Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taro Sees ElixSure Licensing As Means To Building Consumer Awareness

This article was originally published in The Tan Sheet

Executive Summary

Taro Pharmaceuticals is continuing to pursue possible licensing arrangements for its ElixSure NonSpil technology, according to CFO Kevin Connelly

You may also be interested in...



Taro To Expand ElixSure Line, Posts 49% Sales Gain In 2003

Taro Pharmaceutical Industries will expand its ElixSure product line late in the second quarter with Children's ElixSure IB (ibuprofen) Oral Suspension

Taro Foresees OTC Licensing Deals For Cough/Cold Pediatric Delivery System

Taro Consumer Healthcare Products will consider licensing its NonSpil drug delivery system, used in the firm's ElixSure line of cough/cold medicines for children, to other over-the-counter drug manufacturers

Taro ElixSure “Spill-Resistant” Cough/Cold Medicines For Children Debut

Taro Consumer Healthcare Products will back its new ElixSure line of cough/cold medicines for children with $22 mil. in promotional spending through 2004

Related Content

Topics

UsernamePublicRestriction

Register

PS096893

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel